DelveInsight’s “Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
Some of the key facts of the Neurofibromatosis Market Report:
- The Neurofibromatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per Le et al. (2022), neurofibromatosis type 1 makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. Neurofibromatosis type 2 makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410
- Around 16,874 diagnosed cases of NF-2 were found to be prevalent worldwide in 2022, with 10,508 cases found in the US alone. This number of cases is anticipated to increase between 2019 and 2032
- In a research by Ejerskov et al. (2021), five patients (30%) with a mosaic form of neurofibromatosis type 1 (NF1) exhibited plexiform neurofibromas out of a total of 17 patients. In their investigation, which included nine papers as well, the researchers came to the conclusion that out of 126 individuals with MNF1, 19 (15%) of them had a plexiform neurofibroma
- For paediatric patients with neurofibromatosis type 1 (NF1), a rare and disfiguring illness, aged 2 years or older, Selumetinib became the first medication to receive FDA approval in 2020.
- A large number of pharmaceutical companies are entering this illness area as a result of scientific advancements. NFX-179 Gel, Mirdametinib, and FCN-159 are a few new medications
- Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
- Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
- The Neurofibromatosis epidemiology based on type-specific cases analyzed that the prevalent cases of Neurofibromatosis is highest for NF1
- The Neurofibromatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis pipeline products will significantly revolutionize the Neurofibromatosis market dynamics.
Neurofibromatosis Overview
A collection of hereditary diseases known as neurofibromatosis (NF) largely damage the body’s nerve cells’ ability to grow and develop. The three primary varieties of neurofibromatosis are schwannomatosis, neurofibromatosis type 1 (NF1), and type 2 (NF2). These diseases have unique clinical characteristics and are brought on by mutations in various genes.
Get a Free sample for the Neurofibromatosis Market Report
https://www.delveinsight.com/report-store/neurofibromatosis-market
Neurofibromatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Neurofibromatosis Epidemiology Segmentation:
The Neurofibromatosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Neurofibromatosis
- Prevalent Cases of Neurofibromatosis by severity
- Gender-specific Prevalence of Neurofibromatosis
- Diagnosed Cases of Episodic and Chronic Neurofibromatosis
Download the report to understand which factors are driving Neurofibromatosis epidemiology trends @ Neurofibromatosis Epidemiology Forecast
Neurofibromatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched during the study period. The analysis covers Neurofibromatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurofibromatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Neurofibromatosis Therapies and Key Companies
- FCN-159: Fosun Pharmaceutical
- Mirdametinib: SpringWorks Therapeutics
- NFX-179 Gel: NFlection Therapeutics, Inc.
- HL-085: Shanghai Kechow Pharma
- RAD001: Everolimus: Novartis
- NFX-179 gel: NFlection Therapeutics, Inc.
- Selumetinib: Merck Sharp & Dohme LLC
- FCN-159: Shanghai Fosun Pharma
- Trametinib: Novartis
- Binimetinib: Array BioPharma
- REC-2282: Recursion Pharma
- AZD2014: Astrazeneca
- Lapatinib: GlaxoSmithKline
- Icotinib: Betta Pharma
- Bevacizumab: Genentech, Inc.
Discover more about therapies set to grab major Neurofibromatosis market share @ Neurofibromatosis Treatment Market
Scope of the Neurofibromatosis Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
- Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
- Neurofibromatosis Therapeutic Assessment: Neurofibromatosis current marketed and Neurofibromatosis emerging therapies
- Neurofibromatosis Market Dynamics: Neurofibromatosis market drivers and Neurofibromatosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Neurofibromatosis Unmet Needs, KOL’s views, Analyst’s views, Neurofibromatosis Market Access and Reimbursement
To know more about Neurofibromatosis companies working in the treatment market, visit @ Neurofibromatosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Neurofibromatosis Market Report Introduction
2. Executive Summary for Neurofibromatosis
3. SWOT analysis of Neurofibromatosis
4. Neurofibromatosis Patient Share (%) Overview at a Glance
5. Neurofibromatosis Market Overview at a Glance
6. Neurofibromatosis Disease Background and Overview
7. Neurofibromatosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Neurofibromatosis
9. Neurofibromatosis Current Treatment and Medical Practices
10. Neurofibromatosis Unmet Needs
11. Neurofibromatosis Emerging Therapies
12. Neurofibromatosis Market Outlook
13. Country-Wise Neurofibromatosis Market Analysis (2019–2032)
14. Neurofibromatosis Market Access and Reimbursement of Therapies
15. Neurofibromatosis Market Drivers
16. Neurofibromatosis Market Barriers
17. Neurofibromatosis Appendix
18. Neurofibromatosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services